Pernix Therapeutics to Report Third Quarter 2012 Financial Results on November 14, 2012

  Pernix Therapeutics to Report Third Quarter 2012 Financial Results on
  November 14, 2012

     Management to Host a Conference Call on November 14 at 9:00 a.m. EST

Business Wire

THE WOODLANDS, Texas -- November 07, 2012

Pernix Therapeutics Holdings, Inc. (NYSE MKT: PTX), a specialty pharmaceutical
company, today announced that it will release its third quarter 2012 financial
results before the U.S. stock market opens on Wednesday, November 14, 2012 and
has scheduled a conference call at 9:00 am EST that day to discuss the
financial results.

The conference call will feature remarks by Cooper Collins, Chief Executive
Officer, and David Becker, Chief Financial Officer. To participate in the
conference call, please dial (888) 364-3109 (domestic) or (719) 325-2432
(international). Participants can reference the passcode 9218466. Please dial
in approximately 5 minutes prior to the call.

The conference call will also be available via a live listen-only webcast and
can be accessed through the Investor Relations section of the Company’s
website, Please allow extra time prior to the call to visit
the Company’s website and download any software that may be needed to listen
to the webcast.

A replay of the conference call will be available through November 21, 2012,
at (888) 203-1112 (domestic) or (719) 457-0820 (international). The passcode
for the replay is 9218466. An online archive of the webcast will be available
on the Company's website for 30 days following the call.

About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on
the sales, marketing, manufacturing and development of branded, generic and
OTC pharmaceutical products. The Company manages a portfolio of branded and
generic products. The Company’s branded products for the pediatrics market
include CEDAX®, an antibiotic for middle ear infections, NATROBA™, a topical
treatment for head lice marketed under an exclusive co-promotion agreement
with ParaPRO, LLC, and a family of treatments for cough and cold (BROVEX®,
ALDEX® and PEDIATEX®). The Company’s branded products for gastroenterology
include OMECLAMOX-PAK®, a 10-day treatment for H. pylori infection and
duodenal ulcer disease, and REZYST™, a probiotic blend to promote dietary
management. The Company promotes its branded pediatric and gastroenterology
products through its sales force. Pernix markets its generic products through
its wholly-owned subsidiary, Macoven Pharmaceuticals. The Company’s
wholly-owned subsidiary, Pernix Manufacturing, LLC, doing business as Great
Southern Laboratories, manufactures and packages products for the
pharmaceutical industry in a wide range of dosage-forms. A product candidate
utilizing cough-related intellectual property is in development for the U.S.
OTC market. Founded in 1996, the Company is based in The Woodlands, TX.

Additional information about Pernix is available on the Company’s website
located at


Pernix Therapeutics Holdings, Inc.
Joseph T. Schepers, 800-793-2145 ext. 3002
Director, Investor Relations
Press spacebar to pause and continue. Press esc to stop.